The what, why and how of Bayesian clinical trials monitoring.
暂无分享,去创建一个
D J Spiegelhalter | L S Freedman | D. Spiegelhalter | M. Parmar | L. Freedman | M K Parmar | L. Freedman | Mahesh K B Parmar
[1] K. K. Lan,et al. Stochastically curtailed tests in long–term clinical trials , 1982 .
[2] Christopher Jennison,et al. Interim analyses: the repeated confidence interval approach , 1989 .
[3] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[4] T R Fleming,et al. Approaches to monitoring clinical trials. , 1989, Journal of the National Cancer Institute.
[5] Anastasios A. Tsiatis,et al. Exact confidence intervals following a group sequential trial: A comparison of methods , 1988 .
[6] N L Geller,et al. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. , 1987, Biometrics.
[7] P. Macaskill,et al. Stopping rules for clinical trials incorporating clinical opinion. , 1984, Biometrics.
[8] S J Pocock,et al. Interim analyses for randomized clinical trials: the group sequential approach. , 1982, Biometrics.
[9] D. Spiegelhalter,et al. Monitoring clinical trials: conditional or predictive power? , 1986, Controlled clinical trials.
[10] T. Fleming,et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[12] D J Spiegelhalter,et al. Comparison of Bayesian with group sequential methods for monitoring clinical trials. , 1989, Controlled clinical trials.